Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Gubra A/S is a biotechnology firm engaged in two core activities: offering contract research organization (CRO) services for pre-clinical development, and advancing its own internal early-stage drug and target discovery initiatives. Its CRO division provides specialized pre-clinical research and development support to companies in the pharmaceutical and biotechnology sectors. These services encompass a wide range of capabilities, including in vivo pharmacology, tissue analysis, various assay development, molecular pharmacology, bioanalytical testing, next-generation sequencing (NGS), and both two-dimensional and three-dimensional imaging techniques. Established in 2008, the company has its headquarters in Horsholm, Denmark.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is trading at neutral levels on P/FCF.
Target Price
The average target price of GUBRA.CO is 523 and suggests 79.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i